Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
The current therapeutic approach in Waldenström’s macroglobulinemia (WM) is being driven by insights in disease biology and genomic landscape. Bruton’s tyrosine kinase (BTK) plays a key role in signaling pathways for the survival of WM clone. BTK inhibition has changed the treatment landscape of the...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Hematology |
Online Access: | https://doi.org/10.1177/2040620721989586 |